Vivek Jain - 15 Mar 2026 Form 4 Insider Report for ICU MEDICAL INC/DE (ICUI)

Role
Chairman and CEO, Director
Signature
By: Paula Darbyshire, Attorney-in-Fact For: Vivek Jain
Issuer symbol
ICUI
Transactions as of
15 Mar 2026
Net transactions value
$0
Form type
4
Filing time
16 Mar 2026, 16:30:50 UTC
Previous filing
09 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Jain Vivek Chairman and CEO, Director 951 CALLE AMANECER, SAN CLEMENTE By: Paula Darbyshire, Attorney-in-Fact For: Vivek Jain 16 Mar 2026 0001410442

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICUI Common Stock Options Exercise +17,100 +15% $0.000000* 134,106 15 Mar 2026 Direct F1, F2
transaction ICUI Common Stock Tax liability -9,452 -7% $125.85* 124,654 15 Mar 2026 Direct F1
transaction ICUI Common Stock Options Exercise +4,872 +3.9% $0.000000* 129,526 15 Mar 2026 Direct F3
transaction ICUI Common Stock Tax liability -2,693 -2.1% $125.85* 126,833 15 Mar 2026 Direct F3
holding ICUI Common Stock 152,339 15 Mar 2026 by Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ICUI Common Stock Options Exercise -4,872 -100% $0.000000* 0 15 Mar 2026 Common Stock 4,872 $0.000000 Direct F3, F4
transaction ICUI Performance Shares Options Exercise -17,100 -100% $0.000000* 0 15 Mar 2026 Common Stock 17,100 $0.000000 Direct F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These Securities are Performance-based Restricted Stock Units (PRSU).
F2 Represents the settlement of performance stock units granted on 3/15/2023. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 117% of target, resulting in the acquisition of the shares reported herein.
F3 These securities are Restricted Stock Units.
F4 There is neither a purchase price nor an exercise price for the Restricted Stock Units.
F5 There is neither a purchase price nor an exercise price for the PRSUs.